PFE · 10-Q · 2026Q2 · Full report

Product / Drug Pipeline Progress

PFIZER INC · 2026-08-04 · Importance 38 · Surprise 60

Pfizer reported 2026 approvals for Veppanu in ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer in the U.S.; Hympavzi for expanded hemophilia populations in the U.S. and EU; Braftovi for first-line BRAF V600E metastatic colorectal cancer in the EU; and expanded uses of Ibrance and Padcev. The company also received EU approval for the 2026–2027 Comirnaty JN.1 formula and filed additional applications for Tukysa, Padcev, Comirnaty and Talzenna. Padcev remains in late-stage development for bladder-sparing treatment of muscle-invasive bladder cancer, while PF-07872412 is in late-stage development for pediatric pneumococcal disease. Pfizer determined there was no viable U.S. pathway to return Oxbryta to market and voluntarily withdrew its U.S. NDAs on July 31, 2026; a Phase 3 study of investigational sigvotatug vedotin also failed to meet its overall-survival endpoint in previously treated metastatic non-squamous NSCLC.

Key facts

• Phase 3 SigVie-002 study of sigvotatug vedotin did not meet its primary endpoint of a statistically significant improvement in overall survival compared to docetaxel; topline results announced June 2026. source
• Regulatory filings include Tukysa February 2026 (U.S.) and April 2026 (EU); Padcev March 2026 (EU) for perioperative MIBC; Comirnaty June 2026 (U.S.) for certain older/high-risk groups; Talzenna July 2026 (U.S.) with Xtandi. source